52 results about "Intestinal epithelium" patented technology

The invention provides an organoid chip for screening micro-ecological drugs as well as application and a preparation method of the organoid chip, and relates to the technical field of biological medicines. The invention provides a chip integrating intestinal epithelium, a prostate cancer organ and a bladder cancer organ, which is used for researching how microecological preparations, such as probiotics, metabolites and the like, affect tumor microenvironment and immunotherapy effects. The chip can simulate interaction of intestinal tract-tumor axis, and provides an in-vitro evaluation system for precise tumor immunotherapy.

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

The invention relates to a nutritional composition for infants, for children as well as a medical nutritional composition, comprising human milk oligosaccharides and Bifidobacterium breve. The invention further relates to the use of said nutritional composition for strengthening the gut epithelial defense and / or the gut barrier function.

The invention discloses application of knockout or inhibition of intestinal epithelium Ufbp1 gene expression in preparation of medicines for preventing and / or treating obesity, and belongs to the technical field of biological medicines. In order to solve the problems of limited effect, many side effects and the like of the existing obesity treatment means, the invention provides Ufbp1 specifically expressed by intestinal epithelial cells as a new anti-obesity intervention target for the first time. By knocking out or inhibiting intestinal epithelium Ufbp1, weight gain, adipose tissue accumulation, hyperlipidemia, liver fatty degeneration and insulin resistance induced by high fat diet can be effectively resisted. The action mechanism is related to influence on secretion of intestinal apolipoprotein ApoB48 / ApoA1 and further regulation and control of whole body lipid metabolism. The invention provides a clear target and theoretical basis for developing novel anti-obesity therapies such as small-molecule inhibitors and nucleic acid drugs of targeted intestinal epithelium Ufbp1, and has important clinical transformation prospects.

The application discloses a brain hemorrhage prognosis improvement method based on intestinal flora regulation and relates to the technical field of intestinal microecology.The application comprises the following steps: detecting feces, starting intervention if the enterococcus abundance and neuroinflammatory metabolic markers exceed the standard, stopping the use of conventional nutrient solution, perfusing a special component containing sugar analogs, blocking the energy uptake of enterococcus, simultaneously providing a carbon source for beneficial bacteria, synchronously perfusing a microsphere suspension containing a molecular capture function, adsorbing and fixing proinflammatory metabolic waste in the intestinal tract, blocking the blood entry of the proinflammatory metabolic waste, perfusing live bacteria with different functions three times in time sequence, sequentially completing the acidification of the environment, constructing a bacterial membrane barrier and repairing the intestinal epithelium, and re-detecting after each round of intervention, selecting the maintenance period or adjusting the intensity and then recycling according to the decrease of enterococcus and markers.The application can limit the competitive advantage of enterococcus in the utilization of carbon sources after brain hemorrhage by sequentially implementing competitive inhibition of the phosphotransferase system and multi-species ecological niche occupation.

The present disclosure relates to a stem cell-drug carrier including a melatonin-containing drug carrier and a stem cell, and more particularly, to a use of the stem cell for the treatment of intestinal epithelial damage disease and inflammatory bowel disease. According to the present disclosure, it was confirmed that the stem cell-drug carrier continuously released PGE2 and had excellent revival stem cell induction ability. This means that the stem cell-drug carrier of the present disclosure has an excellent intestinal epithelium regeneration effect, and the stem cell-drug carrier of the present disclosure can be used in various fields of treatment of intestinal damage disease and inflammatory bowel disease.

The invention relates to the field of hair growth nutrients, and discloses a nutrient composition for promoting hair growth and a preparation method thereof, the composition comprises a basic hair growth nutrient group and an absorption-promoting synergistic group; the basic hair growth nutrition group comprises the following components in parts by weight: 0.3-0.8 part of ferrous lactate, 2-5 parts of zinc gluconate, 5-8 parts of magnesium stearate, 3-8 parts of a coating material and 17-25 parts of milk mineral salt; the absorption-promoting synergistic group comprises the following components in parts by weight: 0.2-1.5 parts of a black pepper extract, 2-10 parts of lecithin and 2-8 parts of casein phosphopeptides, the black pepper extract and the lecithin are firstly released, an intestinal epithelium channel is opened by utilizing a biological penetration promoting effect, and a pre-permeation state is established; the subsequently released CPP is complexed with divalent metal ions in intestinal juice to prevent precipitation, so that the CPP is synchronously and rapidly absorbed through a pre-opened channel, and the problems of competitive antagonism and difficult absorption of high-dose minerals are effectively solved.

To provide a composition that can suppress the decline in the barrier function of the intestinal epithelium in non-infectious inflammatory bowel disease. [Solution] An agent containing human milk oligosaccharides that suppresses the decline in the barrier function of the intestinal epithelium in non-infectious inflammatory bowel disease.

Present invention relates to a method of treating a disorder by administering an effective amount of a pharmaceutical composition comprising a therapeutic agent bound to a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E (BoNT / E). The p80 is bound to a therapeutic agent, comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. P80 enhances the transportation of the therapeutic agent into the bloodstream for increased bioavailability because thep80 is a tight junction modulator to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery.

The invention provides an FcRn-targeted Brucella multi-epitope nano vaccine, which can realize long-term protection, shows continuous immune memory, has high-frequency hair-growing central B cells (GCB), follicular helper T cells (TFH) and central memory T cells (TCM), and ensures long-term immune surveillance; even six months after immunization, the serum IgG titer is still obviously higher than that of a control group; efficient antigen delivery can be achieved, specifically, a chitosan-based nano-particle system is adopted, and antigen protection and intestinal epithelium uptake are enhanced through FcRn targeted ligand modification; the delivery efficiency can be improved by 10 times, and the gastrointestinal mucosal barrier is overcome; in addition, rapid immune starting can be achieved, multi-dimensional immune response is induced within 14 days after final immunization, and rapid protection is provided for resisting brucella infection.

The invention discloses a traditional Chinese medicine monomer nanoparticle oral delivery system based on intestinal liver circulation and a preparation method thereof, spherical nanoparticles (SA NPs) with the particle size of 194 + / -20 nm are formed through self-assembly of threat resin acid (SA), and the limitation of a traditional nano carrier is broken through: the oral bioavailability reaches 34.7% by utilizing an ASBT-mediated intestinal liver circulation mechanism; the gastric acid environment is tolerated (the pH is stable at 1.5), and after penetrating through the intestinal epithelium, the drug is targeted to ischemic brain tissues; the medicine has carrier-medicine dual functions, and the cerebral infarction volume is reduced by 34.1% when the medicine is singly used; after the neuroprotective peptide NA1 is loaded (the drug loading capacity is 5.8 wt%), the infarct volume is reduced by 68.7% through synergism. The system is suitable for pre-hospital first aid of cerebral apoplexy, and the freeze-dried powder can be stored at normal temperature for 12 months. The delivery system has a great application prospect in preparation of drugs for treating acute ischemic stroke needing rapid brain targeting.

To provide excellent intestinal epithelial-like cells expressing drug-metabolizing enzymes and drug transporters applicable for pharmacokinetic assessment, more specifically, intestinal epithelial-like cells having properties closer to those of primary cultured human intestinal epithelial cells that are difficult to obtain, and to provide production methods thereof.SOLUTION: The present invention is characterized by the monolayer culturing of organoid-derived cells. As a result of analyzing the obtained monolayer film, drug-metabolizing enzymes (each CYP) and drug transporters (PEPT1, MDR1), and the like possessed by small intestinal epithelial cells were expressed and excellent intestinal epithelial-like cells that also have a tight junction function were obtained. From the above, intestinal epithelial-like cells that can be used for pharmacokinetic evaluation and / or drug toxicity evaluation can be efficiently produced.SELECTED DRAWING: Figure 1

本发明属于生物医药与营养学技术领域，具体涉及一种母乳低聚糖在制备改善衰老肠道稳态的产品中的应用。本发明发现不同结构HMOs对衰老小鼠肠上皮稳态的作用不同，3'‑SL和LNnT能更好地促进衰老小鼠肠道屏障及ISCs功能恢复，维持肠上皮稳态。抗生素实验证明HMOs对衰老小鼠肠上皮稳态的有益作用需要肠道微生物群的参与。16S rDNA测序表明3'‑SL和LNnT可重塑肠道微生物群结构。代谢组学分析显示，3'‑SL主要影响能量代谢、氨基酸代谢通路；LNnT主要影响bile secretion,tryptophan metabolism,and phenylalanine metabolism通路。

The invention relates to the technical field of microorganisms, and discloses a bacterial strain capable of promoting intestinal health of children and application of the bacterial strain, the bacterial strain is separated from dairy products and is named as a Bifidobacterium animalis subsp. Lactis BB1000 bacterial strain, and the bacterial strain is named as Bifidobacterium animalis subsp. Lactis BB1000 bacterial strain and is named as Bifidobacterium animalis subsp. Lactis BB1000 bacterial strain. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30861, and the preservation date is June 5, 2024; the strain is resistant to acid and bile salt, has an antibacterial effect, has a function of enhancing intestinal epithelial barrier, and has an anti-inflammatory effect; the strain can be applied to probiotic lozenges.

The invention discloses a salbutamol sulfate oral solution and a preparation method thereof.According to the salbutamol sulfate oral solution, a physical barrier is formed through inclusion of hydroxypropyl-beta-cyclodextrin, and a stability synergistic mechanism is formed through the chelating chemical inhibition effect of EDTA-2Na, so that the oxidative degradation rate of salbutamol sulfate is obviously reduced; in addition, sucralose and peppermint essence are used as flavoring agents for taste, high-sweetness taste modification and cool taste modification are performed, and triple taste masking of HP-beta-CD inclusion, sucralose and peppermint essence is performed, so that the taste score is remarkably improved; by destroying intestinal epithelium tight connection through sodium cholate, the transmembrane transport efficiency is improved, the bioavailability is improved, the apparent permeability coefficient (Papp) is remarkably improved, the problem of low availability caused by the first-pass effect is solved, beagle is orally taken, the bioavailability is remarkably improved, and the application prospect is remarkable.

The invention relates to the technical field of feed preparation, and particularly discloses a biological feed for relieving stress of piglets after weaning and a preparation method thereof.The biological feed comprises, by weight, a basic material and an active material, the active material comprises 4-6 parts of composite mineral particles and 8-12 parts of enteric flavone particles, the composite mineral particles take bentonite as a framework, sodium bicarbonate and an inorganic ion carrier are doped into the inner layer, and an enteric coating is arranged on the outer layer; the enteric flavone particles comprise flavonoid compounds, and enteric coatings are arranged on the outer layers of the enteric flavone particles. The improved composite mineral particles and enteric flavone particles are introduced, buffer salt in the inner layers of the composite mineral particles can locally adjust pH and osmotic pressure in small intestines, the intestinal epithelium electrolyte environment can be stabilized, intestinal acidification caused by weaning stress is relieved, the intestinal flora steady state recovery speed can be remarkably increased, and the diarrhea rate can be remarkably reduced.

A colon-targeted delivery system, a preparation method and application thereof, comprising amifostine, pectin and chitosan; through a chemical amidation reaction, carboxyl in the pectin and amino in the amifostine are connected through an amide bond to form a nanoparticle core PEC-AMF, and the chitosan and the pectin form a nanoparticle coating layer through electrostatic interaction to synthesize CS / PEC-AMF nanoparticles; the colon-targeted delivery system in the application realizes precise and controlled drug release by means of the step-by-step change of pH values in the gastrointestinal tract environment and the catalysis of pectinase in the colon; experiments prove that the delivery system has excellent stability in the stomach and small intestine, and can rapidly release amifostine in the colon, thereby effectively protecting the intestinal epithelium and immune cells from damage caused by radiotherapy, while the pectin regulates the intestinal microecology, protects the normal tissues of the colorectum and does not affect the effect of radiotherapy on tumors.

Disclosed is a drug for preventing and treating diseases related to abnormal intestinal hyperplasia. Specifically disclosed is the following: The accumulation of myeloid-derived inhibitory cells (MDSCs) caused by the reduction of IL-10 is the main cause of abnormal hyperplasia of the intestinal epithelium, and supplementation of IL-10 within myeloid cells at the source helps to restore bone marrow microenvironment homeostasis and reduce the production of pathogenic MDSCs, thereby treating diseases related to abnormal hyperplasia of the intestinal epithelium, such as inflammatory bowel disease and adenomatous polyposis. Disclosed is a recombinant adeno-associated virus vector expressing IL-10. Targeted delivery of IL-10 to myeloid cells is achieved by means of intraosseous injection, avoiding adverse effects caused by systemic administration. This approach offers targeting specificity and safety and provides a new solution for the treatment of diseases related to abnormal intestinal hyperplasia.

The invention discloses a beta-lactoglobulin nanofiber as an adjuvant for oral delivery of therapeutic polypeptide drugs and application of the beta-lactoglobulin nanofiber, and belongs to the technical field of drug delivery adjuvants, the nanofiber is formed by heat treatment of BLG under an acidic condition, and has good gastrointestinal tract stability and severe environment tolerance; in the oral administration process, the nanofibers can temporarily induce the activity of calcium-dependent calpain to be improved, so that the intestinal epithelial permeability is enhanced, and the absorption of polypeptide drugs is facilitated; the rapid recovery of the intestinal barrier function can also be promoted. Insulin is loaded in an enteric capsule coated with 3% of sodium alginate, and by utilizing the BLG nanofiber mediated intestinal barrier regulation effect, compared with subcutaneous injection, the oral administration of insulin shows that the area under a blood glucose curve (AUC) is obviously reduced in a mouse model, and the blood glucose AUC is reduced by about 20.8%. The nanofiber is high in safety and meets the clinical large-scale production requirement.

The application discloses an active peptide for regulating intestinal epithelial mucus barrier function and a preparation method and application thereof, and belongs to the technical field of bioengineering, wherein the amino acid sequence of the active peptide is shown as SEQ ID NO: 1, 2, 3, 4, 5 or 6. The application takes duck skin as raw material, extracts a protein extract, carries out enzymolysis, collects low-molecular-weight peptide components through ultrafiltration grading, carries out freeze-drying to obtain active peptide crude powder, and then carries out screening and separation and purification on the active peptide crude powder through an intestinal epithelial mucus barrier damage model to obtain a target active peptide. The active peptide can significantly improve the secretion level of mucin, promote the expression of a MUC2 gene, maintain the secretion function of goblet cells, restore the integrity of a mucus layer, effectively improve the damaged intestinal epithelial mucus barrier function under the stimulation of inflammation and oxidation stress, and block the contact between pathogenic microorganisms and toxins and epithelial cells. The active peptide obtained by the application has clear structure and definite function, and provides a new way for high-value utilization of livestock and poultry by-products and development of intestinal health products.

The invention belongs to the technical field of targeted drugs, and discloses surface chemical modified intestinal probiotics as well as a preparation method and application thereof, and the method comprises the following steps: dissolving PBA-PEG2000-NHS-ester in a phosphate buffer solution to prepare a PPN solution; mixing the PPN solution with the LGG bacterial suspension, and carrying out incubation reaction under a constant temperature condition to obtain a B-L suspension; and carrying out centrifugal washing on the B-L suspension to obtain the surface modified composite thallus B-L. According to the invention, the LGG is subjected to surface chemical modification through PBA-PEG2000-NHS-ester to prepare the composite thallus B-L, the problem of rapid discharge caused by intestinal colonization resistance and gastrointestinal motility is effectively overcome by utilizing the specific adhesion effect of PBA groups and intestinal epithelium mucus, the LGG is smoothly delivered to the colon part in a targeted manner, long-acting retention is realized, the colonization efficiency of the LGG at the colon part is remarkably improved, and the colonization effect of the LGG at the colon part is improved. The anti-colitis effect is enhanced.

The invention relates to application of taurine in treatment of neonatal necrotizing enterocolitis. Experiments prove that taurine can improve intestinal inflammation of NEC mice and promote intestinal epithelial cell proliferation. The participation of taurine in the regulation and control of NEC inflammation is possibly related to a TLR4 / NF-kappa B signal. Molecular docking data shows that taurine interferes with TLR4 / MD2 protein interaction, and then TLR4 downstream inflammation signal activation is inhibited. NEC inflammation is relieved by inhibiting a TLR4 / NF-kappa B signal, and repair after NEC intestinal epithelium injury is promoted. The application of taurine in neonatal necrotizing enterocolitis is explored from animal and molecular levels, and a theoretical basis is provided for prevention and treatment of neonatal necrotizing enterocolitis.

The invention provides a structural bacteria-based stone flora pharmaceutical composition. The structural bacteria-based stone flora pharmaceutical composition is prepared from live bacteria of bifidobacterium pseudominum aFMT-202, live bacteria of bifidobacterium longum subsp. Longum aFMT-104 and live bacteria of lactobacillus mucosa aFMT-501. The invention also provides a microbial medicinal preparation and a preparation method thereof, and also provides application of the composition in preparation of antidepressant drugs, intestinal anti-inflammatory drugs and antioxidant and anti-aging drugs. The three strains are separated from faeces of healthy adults, have acid resistance, bile salt resistance and intestinal epithelium adhesion capacity, can regulate neurotransmitter balance, enhance intestinal mucosal barrier and up-regulate endogenous antioxidant enzyme activity respectively, have complementary functions and are free of drug resistance and pathogenicity; the composition forms a composite preparation according to a specific ratio, can intervene in depression, chronic intestinal inflammation and aging-related functional decline, solves the limitation that the existing single-target medicine takes effect slowly, has large side effects and cannot intervene comprehensively, and overcomes the defect of clinical multi-target collaborative treatment.

While studies have been made on a method of selectively inducing differentiation from pluripotent stem cells into enterocyte-like cells, provided is an excellent and high-functionality enterocyte-like cell population that can be stably tested for multi-drug metabolism and permeability, and also provided an efficient method of producing cells. The method of inducing differentiation from pluripotent stem cells into enterocyte-like cells includes the following steps (1) and (2): (1) a step of inducing differentiation from pluripotent stem cells into definitive endoderm cells; and (2) a step of culturing the definitive endoderm cells in a system containing CHIR99021, followed by induction of differentiation into intestinal progenitor cells. A cell population of enterocyte-like cells is more effectively obtained by seeding and culturing enterocyte-like cells produced by the method of inducing differentiation, in a base material for organoid production or a base material for two-dimensional culture.

This invention provides the application of *Pleurotus oosporum* polysaccharide in the preparation of drugs and health foods that regulate intestinal barrier function or protect against intestinal damage-related diseases. Its protective effect against a mouse model of intestinal damage induced by sodium dextran sulfate was investigated. Results showed that *Pleurotus oosporum* polysaccharide significantly improved symptoms such as weight loss, loose stools, and colonic atrophy caused by intestinal damage in mice, reduced the disease activity index, inhibited colonic epithelial destruction, inflammatory cell infiltration, and goblet cell necrosis, and enhanced intestinal mucosal barrier function. As a fungus, *Pleurotus oosporum* has high safety and is a potential source of active ingredients against intestinal damage, showing promising development prospects in intestinal barrier protection.

The invention relates to an application of dihydroergomine in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. A brand-new action mechanism is obtained through verification in an inflammatory bowel disease model, wherein TRIM25 can mediate ubiquitination degradation of LSD1 under the inflammatory condition, metabolic disorder of intestinal epithelial tissue is caused, and inflammation is aggravated. According to the application disclosed by the invention, by predicting structural information of combination of the TRIM25 and the LSD1, virtual medicine is used for screening, a dihydroergomine small molecule compound is screened, and the dihydroergomine small molecule compound can well occupy a combination site of interaction of the TRIM25 and the LSD1 and inhibit the interaction of the TRIM25 and the LSD1, so that degradation of the LSD1 is inhibited; in a DSS-induced mouse colitis model, the dihydroergomine can relieve inflammation activation caused by metabolic disorder of intestinal epithelium and well relieve symptoms of the inflammatory bowel disease. In the process, the action mechanism is clear, the effect is remarkable, new application of the dihydroergomine in the aspect of treating the inflammatory bowel disease is realized, and the dihydroergomine has higher clinical application value.

The invention discloses application of asperuloside in preparation of a medicine for preventing and / or treating intestinal epithelial barrier injury. The intestinal epithelium injury mouse model is constructed, and the asperuloside is adopted for administration treatment, so that the asperuloside can promote the intestinal epithelium regeneration of the intestinal epithelium injury animal model, enhance the effect of intestinal stem cells and remarkably promote the expression of a colon regeneration marker and a colon stem cell marker; the compound can be used for preventing and / or treating the intestinal epithelial barrier injury caused by intestinal inflammation, can protect the intestinal tract and relieve intestinal dysfunction, provides more effective medicines for maintaining the intestinal barrier function in clinic, and has important significance in preventing and treating the intestinal epithelial barrier injury caused by the intestinal inflammation and UC.

The invention discloses application of allicin combined with a propolis alcohol extract and a propolis water extract in preparation of a cryptosporidiosis-resistant medicine. The product is used for treating and preventing intestinal infection caused by cryptosporidium parvum, and is particularly suitable for preventing and treating cryptosporidiosis of patients with immunocompromise. Experimental results show that the ABP can effectively interfere with energy metabolism of insect bodies. The compound can significantly inhibit cryptosporidium proliferation, and shows low cytotoxicity. Meanwhile, the compound can enhance the integrity of intestinal epithelial barriers and promote mucous membrane structure repair. In an infected mouse model, the excretion amount of fecal oocysts is remarkably reduced through ABP treatment, and the pathological condition of the intestinal tract is remarkably improved. Serological analysis further shows that the ABP can regulate inflammation and antioxidant balance and inhibit excessive inflammatory response. An intestinal flora sequencing result also shows that the ABP and AWBP treatment can relieve flora structure disorder caused by infection, promote enrichment of beneficial flora and inhibit pro-inflammatory related flora.

The invention discloses a parabacteroides gore DZ001 strain with a cholesterol sulfation function and application of the parabacteroides gore DZ001 strain. The preservation number of the parabacteroides gore DZ001 is GDMCC No: 67376, and the preservation number of the parabacteroides gore DZ001 is H. The strain is separated from faeces of healthy people, a genome carries a sequence for coding sulfotransferase, cholesterol can be specifically catalyzed to generate cholesterol sulfate with higher water solubility, intestinal epithelium reabsorption is blocked, and faeces excretion is promoted. In-vitro experiments show that the strain has excellent cholesterol degradation capacity, gastrointestinal tract tolerance and safe gamma-hemolysis characteristics; in-vivo experiments prove that the traditional Chinese medicine composition can remarkably reduce serum total cholesterol and triglyceride levels of high-fat diet mice, increase high-density lipoprotein cholesterol, improve liver fatty degeneration and regulate blood glucose metabolism. The strain and viable bacteria, supernate or cell-free extract thereof can be widely applied to preparation of cholesterol-reducing health-care foods, medicines and animal feeds, and a new way is provided for prevention and treatment of hypercholesterolemia and related cardiovascular and cerebrovascular diseases.